Pieris discontinues respiratory collaboration with Genentech for scientific reasons

PALVELLA THERAPEUTICS, INC.

Pieris and Genentech jointly ended the respiratory program in May 2023.
Program aimed at locally delivered respiratory therapies using Pieris' Anticalin technology.
Discontinuation attributed to scientific reasons; no financial terms disclosed.
Pieris furnished a June 2023 investor presentation (Exhibit 99.1) with no updated guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.